Elder Pharmaceuticals, a Rs.950 crore plus Mumbai based pharma major, has posted satisfactory performance during the year ended March 2011. Its consolidated net profit went up by 28.4 per cent to Rs.63.55 crore from Rs.49.50 crore in the previous year. Its net sales increased by 33.1 per cent to Rs.959.20 crore from Rs.720.81 crore. EBDITA moved up by 39 per cent to Rs.182.12 crore from Rs.130.98 crore. With improvement in profits, its EPS jumped to Rs.30.95 as against Rs.26.25 in the last year.
The company's employees cost increased by 36.1 per cent to Rs.131.53 crore from Rs.96.65 crore. The depreciation provision went up by 72 per cent to Rs.29.59 crore from Rs.17.19 crore and interest burden increased by 28.4 per cent to Rs.68.10 crore from Rs.53.02 crore.
The equity capital stood at Rs.20.57 crore as at the end of March 2011 and its reserves touched to Rs.898.54 core as against Rs.573.86 crore, a strong growth of 24.9 per cent. Its loans increased by 56.6 per cent to Rs.898.54 crore from Rs.573.86 crore as at the end of March 2010.
The company's standalone net sales increased by 17.7 per cent to Rs.826.48 crore from Rs.702.09 crore and its net profit increased by 26.4 per cent to Rs.71.29 crore.